| Literature DB >> 31779105 |
Iris Samarra1, Bruno Ramos-Molina2,3, M Isabel Queipo-Ortuño3,4, Francisco J Tinahones2,3, Lluís Arola5,6, Antoni Delpino-Rius1, Pol Herrero1, Núria Canela1.
Abstract
Polyamines are involved in the regulation of many cellular functions and are promising biomarkers of numerous physiological conditions. Since the concentrations of these compounds in biological fluids are low, sample extraction is one of the most critical steps of their analysis. Here, we developed a comprehensive, sensitive, robust, and high-throughput LC-MS/MS stable-isotope dilution method for the simultaneous determination of 19 metabolites related to polyamine metabolism, including polyamines, acetylated and diacetylated polyamines, precursors, and catabolites from liquid biopsies. The sample extraction was optimized to remove interfering compounds and to reduce matrix effects, thus being useful for large clinical studies. The method consists of two-step liquid-liquid extraction with a Folch extraction and ethyl acetate partitioning combined with dansyl chloride derivatization. The developed method was applied to a small gender-related trial concerning human serum and urine samples from 40 obese subjects. Sex differences were found for cadaverine, putrescine, 1,3-diaminopropane, γ-aminobutyric acid, N8-acetylspermidine, and N-acetylcadaverine in urine; N1-acetylspermine in serum; and spermine in both serum and urine. The results demonstrate that the developed method can be used to analyze biological samples for the study of polyamine metabolism and its association with human diseases.Entities:
Keywords: LC-MS/MS; acetylpolyamines; liquid biopsies; obesity; polyamine metabolism; polyamines
Mesh:
Substances:
Year: 2019 PMID: 31779105 PMCID: PMC6995533 DOI: 10.3390/biom9120779
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Selected multiple reaction monitoring (MRM), collision energy (CE), retention time, and internal standard (IS) used for each analyte.
| Analyte | Retention Time (min) | Precursor Ion ( | Product Ion ( | CE | IS |
|---|---|---|---|---|---|
| ARG | 5.2 | 408.1 | 70.1 | 40 | ARG-lab |
| 170.3 | 32 | ||||
| AGM | 5.7 | 364.1 | 347.2 | 20 | ARG-lab |
| 170.1 | 28 | ||||
| 155.2 | 52 | ||||
| N-AcDAP | 6.9 | 350.0 | 100.0 | 20 | N8-AcSPD-lab |
| 170.0 | 20 | ||||
| 308.0 | 20 | ||||
| N-AcPUT | 7.4 | 364.1 | 322.0 | 15 | N8-AcSPD-lab |
| 170.1 | 28 | ||||
| 234.0 | 15 | ||||
| GABA | 7.4 | 337.1 | 170.0 | 20 | ARG-lab |
| 296.0 | 8 | ||||
| 157.0 | 36 | ||||
| N1,N8-DiAcSPD | 7.5 | 463.0 | 100.1 | 28 | N1,N8-DiAcSPD-lab |
| 114.1 | 28 | ||||
| 170.2 | 40 | ||||
| N1-AcIsoPUTR | 7.5 | 436.1 | 100.0 | 10 | ARG-lab |
| 126.2 | 20 | ||||
| 170.0 | 30 | ||||
| N-AcCAD | 7.9 | 378.1 | 86.0 | 20 | N8-AcSPD-lab |
| 155.0 | 50 | ||||
| 335.9 | 20 | ||||
| ORN | 11.5 | 599.1 | 170.1 | 48 | LYS-lab |
| 303.1 | 24 | ||||
| N1,N12-DiAcSPM | 11.6 | 753.1 | 100.1 | 32 | N1,N8-DiAcSPD-lab |
| 502.3 | 40 | ||||
| 170.0 | 60 | ||||
| LYS | 12.1 | 613.1 | 170.1 | 52 | LYS-lab |
| 317.1 | 24 | ||||
| N1-AcSPD | 12.4 | 654.1 | 100.1 | 20 | N8-AcSPD-lab |
| 305.1 | 20 | ||||
| N8-AcSPD | 12.4 | 654.1 | 114.1 | 20 | N8-AcSPD-lab |
| 541.1 | 20 | ||||
| 1,3-DAP | 12.9 | 541.1 | 307.0 | 24 | SPD-lab |
| 170.2 | 36 | ||||
| 220.0 | 24 | ||||
| PUT | 13.3 | 555.2 | 219.9 | 28 | PUT-lab |
| 170.1 | 44 | ||||
| CAD | 13.8 | 569.1 | 84.2 | 36 | PUT-lab |
| 170.2 | 44 | ||||
| 186.0 | 36 | ||||
| N1-AcSPM | 15.7 | 944.1 | 100.0 | 44 | SPM-lab |
| 693.3 | 52 | ||||
| 360.2 | 56 | ||||
| SPD | 16.3 | 845.4 | 360.1 | 40 | SPD-lab |
| 170.1 | 60 | ||||
| SPM | 17.5 | 1135.6 | 360.1 | 56 | SPM-lab |
| 170.1 | 60 | ||||
| ARG-lab | 5.2 | 418.1 | 170.3 | 32 | N/A |
| LYS-lab | 12.1 | 621.1 | 170.1 | 52 | N/A |
| N8-AcSPD-lab | 12.4 | 657.0 | 117.2 | 40 | N/A |
| 170.0 | 60 | ||||
| 362.2 | 40 | ||||
| N1,N8-DiAcSPD-lab | 7.5 | 469.0 | 103.1 | 28 | N/A |
| 117.1 | 28 | ||||
| 170.1 | 40 | ||||
| PUT-lab | 13.3 | 563.2 | 219.9 | 28 | N/A |
| 170.1 | 44 | ||||
| SPD-lab | 16.3 | 851.1 | 366.2 | 40 | N/A |
| 170.2 | 60 | ||||
| SPM-lab | 17.5 | 1155.6 | 373.1 | 56 | N/A |
| 170.1 | 60 |
N/A: not applicable.
Recoveries in the percentage of the derivatized analytes for the three purification methods tested. (n = 3) * EA: ethyl acetate.
| Analyte | LLE:EA * | LLE:EA + TFA | SPE |
|---|---|---|---|
| ARG | 4 ± 3 | 75 ± 11 | 20 ± 8 |
| AGM | 108 ± 6 | 97 ± 7 | 50 ± 5 |
| N-AcPUT | 97 ± 6 | 93 ± 13 | 46 ± 6 |
| GABA | 1 ± 2 | 153 ± 37 | 115 ± 10 |
| ORN | 120 ± 15 | 92 ± 8 | 92 ± 7 |
| LYS | 171 ± 62 | 128 ± 10 | 124 ± 8 |
| N1-AcSPD | 99 ± 11 | 81 ± 7 | 75 ± 5 |
| N8-AcSPD | 90 ± 8 | 73 ± 5 | 66 ± 9 |
| 1,3-DAP | 94 ± 7 | 64 ± 8 | 62 ± 7 |
| PUT | 108 ± 9 | 83 ± 11 | 83 ± 4 |
| CAD | 105 ± 9 | 83 ± 9 | 82 ± 5 |
| N1-AcSPM | 96 ± 11 | 66 ± 6 | 57 ± 7 |
| SPD | 161 ± 53 | 100 ± 7 | 98 ± 6 |
| SPM | 108 ± 7 | 52 ± 5 | 37 ± 3 |
Figure 1Comparison of matrix effects (%) in serum samples with the four approaches assessed to extract polyamines and related compounds (n = 3). The Y axis indicates the matrix effects in percentage. Positive values indicate ion enhancement and negative values indicate ion suppression. Metabolites in the X axis are presented in the order of elution.
Figure 2N1-acetylisoputreanine (N1-AcIsoPUTR) product ion spectrum at 30 V of collision energy.
Quality parameters for the analytes in serum using the proposed method.
| Analyte | Recovery (%, | Accuracy | MDL 1 (nM) | MQL 2 (nM) | Repeatability (%RSD | Reproducibility (%RSD | Linear Range (nM) | R2 |
|---|---|---|---|---|---|---|---|---|
| ARG | 82 ± 2.4 | 114.7 ± 2.2 | 22.14 | 73.81 | 4.3 | 1.0 | 75937.4–759373.5 | 0.9998 |
| AGM | 103 ± 7.1 | 84.3 ± 6.5 | 0.04 | 0.14 | 6.7 | 15.6 | 7.7–15.4 | 0.9961 |
| N-AcDAP | N/A | N/A | N/A | N/A | 9.8 | 12.9 | N/A | N/A |
| N-AcPUT | 98 ± 6.7 | 115.2 ± 10.1 | 0.10 | 0.35 | 8.8 | 1.9 | 18.0–180.0 | 0.9983 |
| GABA | 110 ± 3.7 | 95.7 ± 14.9 | 1.08 | 3.60 | 5.7 | 3.7 | 290.9–581.8 | 0.9944 |
| N1,N8-DiAcSPD | 107 ± 8.3 | 101.3 ± 4.3 | 0.01 | 0.03 | 9.1 | 1.3 | 0.9–43.6 | 0.9999 |
| N1-AcIsoPUTR | N/A | N/A | N/A | N/A | 18.3 | 12.8 | N/A | N/A |
| N-AcCAD | N/A | N/A | N/A | N/A | 3.3 | 1.2 | N/A | N/A |
| ORN | 92 ± 4.1 | 109 ± 3.8 | 0.84 | 2.81 | 2.5 | 1.3 | 94887.9–948879.1 | 0.9936 |
| N1,N12-DiAcSPM | 111 ± 4.8 | 101.2 ± 7.2 | 0.004 | 0.01 | 4.3 | 1.3 | 0.6–5.6 | 0.9962 |
| LYS | 121 ± 3.4 | 107.9 ± 1.6 | 1.99 | 6.66 | 2.4 | 5.9 | 109446.6–1094466.1 | 0.9959 |
| N1-AcSPD | 95 ± 4.5 | 101.4 ± 14.3 | 0.02 | 0.08 | 3.5 | 3.3 | 115.3–5764.8 | 0.9995 |
| N8-AcSPD | 88 ± 5.1 | 98.3 ± 3.5 | 0.01 | 0.03 | 4.2 | 6.1 | 115.3–230.6 | 0.9999 |
| 1,3-DAP | 96 ± 11.2 | 119.7 ± 5 | 0.41 | 1.38 | 3.7 | 21.2 | 20.4–102.0 | 0.9855 |
| PUT | 93 ± 8.1 | 99.5 ± 3.8 | 0.15 | 0.51 | 4.2 | 3.6 | 113.4–567.2 | 0.9990 |
| CAD | 93 ± 4.8 | 101.2 ± 3.9 | 0.03 | 0.09 | 3.6 | 7.8 | 9.8–19.6 | 0.9998 |
| N1-AcSPM | 87 ± 7.8 | 104.4 ± 6.6 | 0.02 | 0.08 | 5.6 | 8.8 | 2.8–14.1 | 0.9999 |
| SPD | 98 ± 5.8 | 115.7 ± 3.9 | 0.01 | 0.05 | 7.1 | 12.1 | 68.8–3442.3 | 0.9999 |
| SPM | 100 ± 5.6 | 118.4 ± 6.5 | 0.04 | 0.14 | 2.1 | 0.9 | 14.8–296.5 | 0.9992 |
1 Method detection limit (MDL). 2 Method quantification limit (MQL). Not applicable (N/A).
Amounts of polyamines, polyamine precursors, and catabolites in serum and urine from 40 obese patients.
| Analyte (Mean ± SD) | Serum (nM) | Urine (nmol/mg Creatinine) | ||||||
|---|---|---|---|---|---|---|---|---|
| Obese Male Patients | Obese Female Patients | FC 1 | Obese Male Patients | Obese Female Patients | FC | |||
| ARG | 117.3 × 103 ± 27.6 × 103 | 114.9 × 103 ± 19.9 × 103 | - | >0.05 | 28.0 ± 25.1 | 24.4 ± 15.6 | - | >0.05 |
| AGM | 0.1 ± 0.1 | 0.1 ± 0.1 | - | >0.05 | 0.2 × 10−3 ± 0.3 × 10−3 | 0.8 × 10−3 ± 3.4 × 10−3 | - | >0.05 |
| N-AcDAP | 1.7 ± 0.6 | 1.8 ± 0.6 | - | >0.05 | 0.6 ± 0.4 | 0.8 ± 0.4 | - | >0.05 |
| N-AcPUT | 22.5 ± 8.4 | 23.6 ± 8.0 | - | >0.05 | 14.7 ± 6.5 | 16.8 ± 7.0 | - | >0.05 |
| GABA | 214.9 ± 60.4 | 192.5 ± 50.5 | - | >0.05 | 0.5 ± 0.2 | 0.9 ± 0.4 | 1.54 | ≤0.05 * |
| N1,N8-DiAcSPD | 0.8 ± 0.6 | 0.8 ± 0.5 | - | >0.05 | 0.9 ± 0.4 | 1.0 ± 0.5 | - | >0.05 |
| N1-AcIsoPUTR | 10.1 ± 6.3 | 8.0 ± 5.2 | - | >0.05 | 0.4 ± 0.2 | 0.4 ± 0.3 | - | >0.05 |
| N-AcCAD | 9.3 ± 12.3 | 13.6 ± 19.9 | - | >0.05 | 5.2 ± 7.3 | 11.0 ± 14.5 | 2.08 | ≤0.05 * |
| ORN | 151.7 × 103 ± 29.7 × 103 | 155.7 × 103 ± 30.0 × 103 | - | >0.05 | 22.8 ± 43.4 | 14.8 ± 6.9 | - | >0.05 |
| N1,N12-DiAcSPM | 0.7 ± 0.4 | 0.7 ± 0.4 | - | >0.05 | 0.2 ± 0.2 | 0.2 ± 0.1 | - | >0.05 |
| LYS | 308.7 × 103 ± 44.9 × 103 | 323.9 × 103 ± 41.6 × 103 | - | >0.05 | 0.3 × 103 ± 0.4 × 103 | 0.1 × 103 ± 0.1 × 103 | - | >0.05 |
| N1-AcSPD | 81.3 ± 22.8 | 73.5 ± 29.9 | - | >0.05 | 4.5 ± 2.2 | 5.4 ± 2.3 | - | >0.05 |
| N8-AcSPD | 37.0 ± 8.3 | 34.2 ± 7.6 | - | >0.05 | 4.7 ± 1.4 | 5.8 ± 1.3 | 1.24 | ≤0.05 * |
| 1,3-DAP | 8.4 ± 2.5 | 9.1 ± 4.0 | - | >0.05 | 0.1 ± 0.1 | 0.2 ± 0.1 | 1.91 | ≤0.01 ** |
| PUT | 76.5 ± 28.5 | 78.6 ± 28.1 | - | >0.05 | 0.7 ± 0.6 | 1.4 ± 1.0 | 2.51 | ≤0.01 ** |
| CAD | 1.1 ± 0.8 | 1.3 ± 1.0 | - | >0.05 | 0.1 ± 0.2 | 0.6 ± 0.8 | 7.32 | ≤0.01 ** |
| N1-AcSPM | 1.8 ± 0.7 | 1.4 ± 0.5 | 1.33 | ≤0.05 * | 4.7 × 10−3 ± 4.9 × 10−3 | 8.8 × 10−3 ± 11.1 × 10−3 | - | >0.05 |
| SPD | 176.8 ± 79.3 | 134.5 ± 40.6 | - | >0.05 | 0.3 ± 0.3 | 0.2 ± 0.2 | - | >0.05 |
| SPM | 31.6 ± 9.8 | 20.9 ± 7.4 | 1.52 | ≤0.01 ** | 3.0 ± 3.7 | 0.1 ± 0.1 | 14.38 | ≤0.01 ** |
1 Fold change (FC). FC is only specified for the statistically significant analytes (p ≤ 0.05). Otherwise it has been indicated as “-”. * Significant at p ≤ 0.05. ** Significant at p ≤ 0.01.
Figure 3Chromatogram of a serum sample with the quantitative transition used for each analyte.